JMP Securities Reiterates a Buy Rating on Sarepta Therap.

By Carrie Williams

In a report released today, Liisa Bayko from JMP Securities reiterated a Buy rating on Sarepta Therap. (NASDAQ: SRPT). The company’s shares opened today at $37.58.

According to, Bayko is a 4-star analyst with an average return of 5.6% and a 56.0% success rate. Bayko covers the Healthcare sector, focusing on stocks such as Achillion Pharmaceuticals, Anthera Pharmaceuticals, and Conatus Pharmaceuticals.

Currently, the analyst consensus on Sarepta Therap. is Strong Buy and the average price target is $74.57, representing a 98.4% upside.

In a report issued on November 3, Robert W. Baird also reiterated a Buy rating on the stock with a $102 price target.

The company has a one year high of $63.73 and a one year low of $8. Currently, Sarepta Therap. has an average volume of 4.3M.

Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SRPT in relation to earlier this year. Earlier this month, Edward Kaye, the SVP Interim CEO & CMO of SRPT bought 3,000 shares for a total of $24,840.

Sarepta Therapeutics, Inc. is a biopharmaceutical company, which is engaged in the discovery and development of unique RNA-based therapeutics for the treatment of rare and infectious diseases. The company is primarily focused on rapidly advancing the development of its potentially disease modifying duchenne muscular dystrophy drug candidates. Sarepta Therapeutics was founded on July 22, 1980 and is headquartered in Cambridge, MA.